Navigation Links
Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix
Date:2/11/2009

nterology. Since the 1950s, the company has pioneered the research, development and marketing of pharmaceutical products based on natural, hypothalamus and pituitary-based peptide hormones.

Headquartered in Switzerland, Ferring has commercial subsidiaries in over 45 countries and its products are available in more than 70 countries. The company's R&D centers are located in: Saint-Prex (Switzerland), San Diego and Parsippany (U.S.), Copenhagen (Denmark), Mumbai (India) and Beer Tuvia (Israel).

Speaking at the opening of the new R&D facility, Chairman Frederik Paulsen (son of the company's founder Dr. Frederik Paulsen) said: "Historically, Ferring is one of the first pharmaceutical companies to have embarked upon peptide research. It is an integral part of our heritage and it is part of our vision today that our Research Institute in San Diego will take this heritage into the future.

"The most pertinent example of the strength and promise of peptide therapy is our new prostate cancer treatment, degarelix. The research towards degarelix occurred in San Diego with our institute and academic research partners. The molecule was ultimately discovered by Ferring Research Institute San Diego," Chairman Paulsen said.

Ferring Research Institute Managing Director and Vice President-Research Pierre Riviere added, "We're excited about the future of Ferring on the West Coast and in the U.S. with the expanded facility and the approval to launch degarelix. Since first establishing our presence in San Diego in 1996, we've maintained our focus on peptide research excellence so that we can become an integral part of the Southern California biotech community. We're very committed to the region as it continues to offer access to great scientific talent, top academic institutions, and world-class research - all of which offer opportunities for our organization, the industry and those who can benefit from our ther
'/>"/>

SOURCE Ferring Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
3. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
7. Jazz Pharmaceuticals to Present at UBS Global Life Sciences Conference
8. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
9. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
10. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... history lessons often have it that American Indians largely ... chicken pox, influenza and tuberculosis brought to the New ... vary, about 20 million people lived in the Americas ... them were killed by European diseases., But new research ... University and Johannes Krause of the University of Tubingen ...
(Date:8/20/2014)... 2014 Neurotrope, Inc. (OTCQB: NTRP) today ... to provide an update on Company activities. Access ... numbers:(888) 505-4369 (U.S. and Canada) or (719) 325-2315 ... , under "Investor Relations"The teleconference replay will be ... 2, 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... 20, 2014  Decision Resources Group finds that the vascular access ... , India and China ... roughly equal to the size of the United States ... will experience much faster growth as a result of strong economic ... Other key findings from Decision Resources Group,s coverage of the BRIC ...
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Neurotrope To Host Conference Call 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2
... company adds new apoAI measurement and apoB/apoAI ratio to ... March 17 /PRNewswire/ -- Atherotech, ... Cholesterol Test in booth #1263 at ACC.09, the American ... The annual meeting takes place March 29-31, 2009, at ...
... Mass., March 17 The pro bono healthcare ... ), has announced that its newly instituted Safe ... Lutheran Health System of La Crosse, Wisconsin. The ... outstanding accomplishments in safe patient handling, safe lifting, ...
... March 17 Cardiorobotics, Inc., a ... use in a wide range of applications, including: ... appointment of Dr. Samuel Straface in the position ... that Dr. Straface has joined Cardiorobotics in this ...
Cached Biology Technology:Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando 2Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando 3Gundersen Lutheran Health System is Recognized for Safe Lifting Leadership 2Gundersen Lutheran Health System is Recognized for Safe Lifting Leadership 3Cardiorobotics Announces New CEO, PLSG Executive-in-Residence to Lead Company 2Cardiorobotics Announces New CEO, PLSG Executive-in-Residence to Lead Company 3
(Date:8/20/2014)... burning spiciness that is irresistible to some, but intolerable ... using their findings to develop a new drug candidate ... by inflammation or other problems. They reported their progress ... trials, in ACS, Journal of Medicinal Chemistry . ... scientists had pegged a compound called capsaicin as the ...
(Date:8/20/2014)... by researchers at the University of Missouri School of ... life-threatening heart condition caused by muscular dystrophy. , ... Ph.D., the leading author of the study and assistant ... of Molecular Microbiology and Immunology. "This is just a ... a treatment for people with this devastating heart condition, ...
(Date:8/20/2014)... and POINT ROBERTS, Washington , August ... a Key Role in Addressing Security Concerns in the Payment ... global news source covering leading sectors including biometrics, issues commentary ... Jason Peaslee , Managing Partner at Thrive ... Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: NXTD) ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
... Tampa, Fla. (April 11, 2011) ... be the most efficacious of three kinds of clinically ... in the current issue of Cell Transplantation ... to researchers in Seoul, South Korea, transplantation of PDLSCs ...
... Human umbilical cord blood-derived mensenchymal stem cells (uMSCs) have ... (LN) when transplanted into mouse models of systemic lupus ... immune system aberrations" characterized by diverse clinical conditions, including ... patients with SLE., The beneficial results were reported in ...
... Scientists have moved a step closer to being able to ... technique to map both the connections and functions of nerve ... A new area of research is emerging in the neuroscience ... our genetic make-up, connectomics aims to map the brain,s connections ...
Cached Biology News:Periodontal stem cell transplantation shows promise 2Umbilical cord blood-derived stem cells studied for lupus therapy 2Mapping the brain: New technique poised to untangle the complexity of the brain 2Mapping the brain: New technique poised to untangle the complexity of the brain 3
...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... types of yeast two-hybrid studies, including complex interaction studies ... Choice of two bait vectors for maximum flexibility and ... Triple reporter strain NMY51 ensures an ... Complete set of controls: pLexA-p53, pLexA-lamin C and ...
Biology Products: